In recent years, the global prevalence of myopia has reached an unprecedented level, especially in East Asia. Multitude of studies has shown that the etiology of myopia is complex. Some researchers have sugge... … [Read more...] about The role of the KEAP1-NRF2 signaling pathway in form deprivation myopia guinea pigs
News
A case of acute idiopathic maculopathy in both eyes with peripheral vascular occlusion
This study aimed to present a case of bilateral symmetric onset of acute idiopathic maculopathy after high fever with peripheral vascular occlusion. … [Read more...] about A case of acute idiopathic maculopathy in both eyes with peripheral vascular occlusion
VIDEO: Axpaxli may disrupt treatment paradigm for retinal vascular diseases
November 13, 2024 3 min watch NEW YORK — In this Healio Video Perspective from OSN New York, Sanjay Nayak, MBBS, PhD, of Ocular Therapeutix discusses Axpaxli for the treatment of retinal vascular diseases. According to Nayak, Axpaxli (axitinib intravitreal implant) is “a single injection, a single completely bioabsorbable hydrogel that … [Read more...] about VIDEO: Axpaxli may disrupt treatment paradigm for retinal vascular diseases
VIDEO: Oral Stargardt’s disease treatment focuses on reducing vitamin A dimerization
November 13, 2024 2 min watch CHICAGO — In this Healio Video Perspective from Eyecelerator@AAO, Michel Dahan, CEO of Alkeus Pharmaceuticals discusses ALK-001, the company’s oral therapy for the treatment of Stargardt’s disease and age-related macular degeneration. ALK-001 (gildeuretinol) is “a new chemical entity designed to lower dimerization in the retina and do so … [Read more...] about VIDEO: Oral Stargardt’s disease treatment focuses on reducing vitamin A dimerization
VIDEO: More durable retinal treatments can help improve clinical capacity, patient care
November 13, 2024 2 min watch BARCELONA, Spain – In this Healio Video Perspective from the Euretina congress, David Wong, MD, shares his thoughts on the advantages of new drugs for retinal conditions including age-related macular degeneration. Clinicians are facing “a tsunami of injections,” he said, because new options are now becoming available for retinal … [Read more...] about VIDEO: More durable retinal treatments can help improve clinical capacity, patient care
Atsena Therapeutics and Nippon Shinyaku enter exclusive license agreement for ATSN-101
Atsena Therapeutics Inc. and Nippon Shinyaku Co., Ltd. have entered into an exclusive license agreement for the commercialization of ATSN-101 in the United States and for the development and commercialization of ATSN-101 in Japan. This collaboration aims to advance ATSN-101, an investigational gene therapy for Leber congenital amaurosis (LCA) caused by biallelic mutations in … [Read more...] about Atsena Therapeutics and Nippon Shinyaku enter exclusive license agreement for ATSN-101
Study examines the use of AI–based detection of diabetic retinopathy in the US
A team of researchers recently conducted a cohort study to investigate the adoption of artificial intelligence (AI)-based diabetic retinopathy (DR) detection in US healthcare settings, highlighting both the promise and slow uptake of this technology.In the study, the researchers traced the use of Current Procedural Terminology code 92229, an AI-based screening reimbursement … [Read more...] about Study examines the use of AI–based detection of diabetic retinopathy in the US
New canalicular gel shows promise for dry eye treatment
Reviewed by Mark Packer, MD; and Eric Donnenfeld, MDIn June 2024, a canalicular gel device (Lacrifill, Nordic Pharma) was introduced to the US market, and a recent study has shown it to be a safe, well-tolerated, and effective treatment for dry eye.1 This device offers a new option for managing a condition that affects millions of patients.A study, led by first author Mark … [Read more...] about New canalicular gel shows promise for dry eye treatment
Cencora to acquire Retina Consultants of America for upwards of $5.1 Billion
The Healthcare Private Equity team has advised Retina Consultants of America (RCA) and Webster Equity Partners in the sale of RCA to Cencora for approximately $4.6 billion in cash and up to $500 million in aggregate contingent consideration, subject to the successful completion of certain predefined business objectives. The transaction is subject to the satisfaction of … [Read more...] about Cencora to acquire Retina Consultants of America for upwards of $5.1 Billion
Novel prognostic factors and combination therapy outcomes in Morbihan disease: insights from an Asian population
This study aimed to identify novel prognostic factors for Morbihan disease (MD) treatment outcomes and evaluate the efficacy of combination therapy in an Asian population, addressing the gaps in current unders... … [Read more...] about Novel prognostic factors and combination therapy outcomes in Morbihan disease: insights from an Asian population